Michelle Devissaguet

Title: Michelle Devissaguet: Innovator in Anti-Ischemic Pharmaceutical Compositions

Introduction

Michelle Devissaguet is a notable inventor based in Neuilly-sur-Seine, France. She has made significant contributions to the field of pharmaceuticals, particularly in developing compositions that address ischemic conditions. Her innovative approach has led to the creation of a unique pharmaceutical composition that has garnered attention in the medical community.

Latest Patents

Michelle holds a patent for her invention titled "Anti-Ischemic Pharmaceutic Compositions." This novel composition features a high dosage of the dihydrochloride of 1-(2,3,4-trimethoxybenzyl)piperazine, combined with a disintegrating agent such as mannitol or sodium carboxymethyl starch. The formulation is designed to provide a virtually instantaneous action within the organism, making it particularly effective for patients requiring rapid relief from ischemic conditions. The recommended dosage for administration is between 20 to 80 mg per day.

Career Highlights

Michelle is associated with Science Union et Cie, where she continues to advance her research and development efforts. Her work is characterized by a commitment to improving patient outcomes through innovative pharmaceutical solutions.

Collaborations

Michelle collaborates with Jean-Claude Arnaud, leveraging their combined expertise to enhance the effectiveness of their pharmaceutical compositions.

Conclusion

Michelle Devissaguet's contributions to the field of pharmaceuticals, particularly her patent for anti-ischemic compositions, highlight her role as an innovator dedicated to improving healthcare solutions. Her work exemplifies the impact of innovation in addressing critical medical needs.